Immunic (NASDAQ:IMUX) Shares Down 2.1% – Should You Sell?

Shares of Immunic, Inc. (NASDAQ:IMUX) fell 2.1% on Wednesday . The stock traded as low as $0.60 and last traded at $0.6094. 1,023,047 shares changed hands during trading, a decline of 31% from the average session volume of 1,474,176 shares. The stock had previously closed at $0.6222.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. D. Boral Capital reissued a “buy” rating and set a $8.00 price target on shares of Immunic in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a research report on Thursday, October 16th. HC Wainwright reduced their price target on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 14th. Finally, Roth Mkm began coverage on Immunic in a research report on Friday, November 7th. They set a “buy” rating and a $3.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Immunic currently has an average rating of “Buy” and an average price target of $7.40.

Immunic Trading Down 2.1%

The firm’s 50-day moving average is $0.64 and its two-hundred day moving average is $0.78. The stock has a market cap of $73.30 million, a price-to-earnings ratio of -0.73 and a beta of 1.54.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. On average, analysts predict that Immunic, Inc. will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMUX. Qube Research & Technologies Ltd purchased a new position in Immunic in the 3rd quarter valued at $29,000. Two Sigma Investments LP acquired a new stake in shares of Immunic in the third quarter valued at about $52,000. HB Wealth Management LLC purchased a new position in shares of Immunic in the third quarter worth about $81,000. Virtu Financial LLC acquired a new position in Immunic during the third quarter worth about $99,000. Finally, GSA Capital Partners LLP acquired a new position in Immunic during the third quarter worth about $170,000. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.